Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.

Autor: Maysa Abu-Khalaf, Vinni Juneja, Gina Chung, Michael DiGiovanna, Rebecca Sipples, Meghan McGurk, Daniel Zelterman, Bruce Haffty, Michael Reiss, Frans Wackers, Forrester Lee, Barbara Burtness
Předmět:
Zdroj: Breast Cancer Research & Treatment; Sep2007, Vol. 104 Issue 3, p341-349, 9p
Abstrakt: Abstract Objectives  This study evaluated the incidence of late cardiotoxicity after dose-dense and -intense adjuvant sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) for breast cancer (BC) with ≥ 4 involved ipsilateral axillary lymph nodes. Methods  Patients were enrolled from 1994 to 2001 after definitive BC surgery if ≥4 axillary nodes were involved. Planned treatment was A 90 mg/m2 q 14 days � 3, T 250 mg/m2 q 14 days � 3, C 3 g/m2 q 14 days � 3 with filgrastim (G) support. Left ventricular ejection fraction (LVEF) was monitored using equilibrium radionuclide angiography (ERNA) before the initiation of chemotherapy, and after three cycles of each chemotherapeutic agent. At a median follow-up of 7 years, we obtained ERNA scans on 32 patients to evaluate the long-term cardiotoxicity of this regimen. Results  Eighty-five eligible patients enrolled on the treatment protocol. Clinical heart failure developed in one patient. Seven (8%) patients had LVEF  Conclusions  Late development of asymptomatic decline in cardiac function may occur after dose-dense and -intense adjuvant therapy, but is uncommon. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: